02.08.2021 Evotec SE  DE0005664809

DGAP-Adhoc: Evotec SE Announces Confidential Submission of Draft Registration Statement on Form F-1 with the U.S. Securities and Exchange Commission for a Proposed Offering of American Depositary Shares


 

DGAP-Ad-hoc: Evotec SE / Key word(s): Miscellaneous
Evotec SE Announces Confidential Submission of Draft Registration Statement on Form F-1 with the U.S. Securities and Exchange Commission for a Proposed Offering of American Depositary Shares

02-Aug-2021 / 11:32 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.


Hamburg, Germany - Evotec SE (Frankfurt Stock Exchange; EVT, MDAX/TecDAX, ISIN: DE0005664809, WKN 566480) announces that it confidentially submitted a Registration Statement on Form F-1 ("Registration Statement") with the U.S. Securities and Exchange Commission ("SEC") for a proposed offering and sale in the United States of shares of Evotec represented by American Depositary Shares ("ADSs"). The Registration Statement has not yet become effective and the final number of ADSs to be offered and their price have not yet been determined.

Evotec's shares are listed on the regulated market of the Frankfurt Stock Exchange in Germany with additional admission obligations of the Prime Standard Segment. Evotec will seek a secondary listing of the ADSs on the Nasdaq Global Select Market in the United States under the ticker symbol "EVO". The new shares underlying the ADSs will be issued from Evotec's authorized capital. The first day of trading of the ADSs is expected to occur during the second half of 2021, however, this timing remains subject to change.

The ADSs referred to in this announcement are to be offered only by means of a registration statement on Form F-1 approved by the SEC. In accordance with applicable capital markets requirements, Evotec will announce when the registration statement has been approved by the SEC, including further details, such as final number and price of ADS.

- End of the ad hoc release -

This announcement does not constitute an offer to sell or the solicitation of an offer to buy any securities. Any offers, solicitations, or offers to buy, or any sales of securities will be made in accordance with the registration requirements of the U.S. Securities Act of 1933, as amended ("Securities Act"), and other applicable securities laws. This announcement is being issued in accordance with Rule 135 under the Securities Act and other applicable securities laws. This public disclosure of inside information does not constitute a prospectus.

This announcement contains forward-looking statements concerning future events, including the proposed offering and listing of Evotec's securities. Words such as "anticipate," "believe," "could," "estimate," "expect," "intend," "may," "might," "plan," "potential," "should," "target," "would" and variations of such words and similar expressions are intended to identify forward-looking statements. Such statements include comments regarding completion of the offering. These forward-looking statements are based on the information available to, and the expectations and assumptions deemed reasonable by Evotec at the time these statements were made. No assurance can be given that such expectations will prove to have been correct. These statements involve known and unknown risks and are based upon a number of assumptions and estimates, which are inherently subject to significant uncertainties and contingencies, many of which are beyond the control of Evotec. Evotec expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Evotec's expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based.

Contact:
Dr Werner Lanthaler, Chief Executive Officer

Evotec SE
Manfred Eigen Campus
Essener Bogen 7
22419 Hamburg, Germany

Phone: +49.(0)40.560 81-242
Email: [email protected]


02-Aug-2021 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de


Language: English
Company: Evotec SE
Manfred Eigen Campus / Essener Bogen 7
22419 Hamburg
Germany
Phone: +49 (0)40 560 81-0
Fax: +49 (0)40 560 81-222
E-mail: [email protected]
Internet: www.evotec.com
ISIN: DE0005664809
WKN: 566480
Indices: MDAX, TecDAX
Listed: Regulated Market in Berlin, Frankfurt (Prime Standard); Regulated Unofficial Market in Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange
EQS News ID: 1223297

 
End of Announcement DGAP News Service

1223297  02-Aug-2021 CET/CEST

fncls.ssp?fn=show_t_gif&application_id=1223297&application_name=news&site_id=boersengefluester_html


Die wichtigsten Finanzdaten auf einen Blick
  2017 2018 2019 2020 2021 2022 2023e
Umsatzerlöse1 257,63 375,41 446,44 500,92 618,03 751,45 835,00
EBITDA1,2 57,22 95,46 123,14 51,77 101,65 102,51 122,00
EBITDA-Marge3 22,21 25,43 27,58 10,33 16,45 13,64
EBIT1,4 37,50 77,46 62,59 48,52 41,00 20,85 0,00
EBIT-Marge5 14,56 20,63 14,02 9,69 6,63 2,78 0,00
Jahresüberschuss1 24,00 84,06 37,23 6,25 215,51 -175,66 0,00
Netto-Marge6 9,32 22,39 8,34 1,25 34,87 -23,38 0,00
Cashflow1,7 10,83 156,24 42,22 44,72 122,24 203,11 0,00
Ergebnis je Aktie8 0,16 0,46 0,25 0,04 1,30 -0,99 -0,50
Dividende8 0,00 0,00 0,00 0,00 0,00 0,00 0,00
Quelle: boersengefluester.de und Firmenangaben

  Geschäftsbericht 2022 - Kostenfrei herunterladen.  
1 in Mio. Euro; 2 EBITDA = Ergebnis vor Zinsen, Steuern und Abschreibungen; 3 EBITDA in Relation zum Umsatz; 4 EBIT = Ergebnis vor Zinsen und Steuern; 5 EBIT in Relation zum Umsatz; 6 Jahresüberschuss (-fehlbetrag) in Relation zum Umsatz; 7 Cashflow aus der gewöhnlichen Geschäftstätigkeit; 8 in Euro; Quelle: boersengefluester.de

Wirtschaftsprüfer: BDO

INVESTOR-INFORMATIONEN
©boersengefluester.de
Evotec
WKN Kurs in € Einschätzung Börsenwert in Mio. €
566480 14,375 Halten 2.552,17
KGV 2025e KGV 10Y-Ø BGFL-Ratio Shiller-KGV
21,14 35,49 0,58 81,22
KBV KCV KUV EV/EBITDA
2,24 12,57 3,40 25,77
Dividende '22 in € Dividende '23e in € Div.-Rendite '23e
in %
Hauptversammlung
0,00 0,00 0,00 10.06.2024
Q1-Zahlen Q2-Zahlen Q3-Zahlen Bilanz-PK
22.05.2024 14.08.2024 08.11.2023 24.04.2024
Abstand 60Tage-Linie Abstand 200Tage-Linie Performance YtD Performance 52 Wochen
0,46% -21,36% -32,45% -23,21%
    
Weitere Ad-hoc und Unternehmensrelevante Mitteilungen zu Evotec SE  ISIN: DE0005664809 können Sie bei EQS abrufen


Biotechnologie , 566480 , EVT , XETR:EVT